Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

JAMA

Volumn 304, Issue 3, 2010, Pages 275-283

  Cooper, Cristine J ^a   Metch, Barbara ^a   Dragavon, Joan ^b   Coombs, Robert W ^b   Baden, Lindsey R ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RIBOSOME DNA; VIRUS DNA; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS 5; ADULT; ALGORITHM; ALPHA VIRUS; ANTIGEN SPECIFICITY; ARTICLE; CANARYPOX VIRUS; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG DOSE ESCALATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; SOUTH AMERICA; THAILAND; TREATMENT OUTCOME; UNITED STATES; WESTERN BLOTTING;

EID: 77954713270     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.926     Document Type: Article

References (30)

1. Global Summary of the AIDS epidemic, December 2008. World Health Organization Web site. http://www.who.int/hiv/data/en/index.html. Accessed March 15, 2010.
2. Pialoux G, Hocini H, Perusat S, et al; ANRS VAC14 Study Group. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers. Vaccine. 2008;26(21):2657-2666.
3. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis. 2003;188(2):219-227.
4. Pitisuttithum P, Gilbert P, Gurwith M, et al; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661-1671.
5. Goepfert PA, Tomaras GD, Horton H, et al; NIAID HIV Vaccine Trials Network. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25(3):510-518.
6. Graham BS, Koup RA, Roederer M, et al; Vaccine Research Center 004 Study Team. Phase 1 safety and immunogenicity evaluation of amulticlade HIV-1 DNA candidate vaccine. J Infect Dis. 2006;194(12):1650-1660.
7. Mulligan MJ, Russell ND, Celum C, et al; NIH/NIAID/DAIDS HIV Vaccine Trials Network. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses. 2006;22(7):678-683.
8. Spearman P, Kalams S, Elizaga M, et al; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27(2):243-249.
9. Jin X, Newman MJ, De-Rosa S, et al; NIAID HIV Vaccine Trials Network. A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a phase I clinical trial in HIV-uninfected adults. Vaccine. 2009;27(50):7080-7086.
10. Gorse GJ, Baden LR, Wecker M, et al; HIV Vaccine Trials Network. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine. 2008;26(2):215-223.
11. Russell ND, Graham BS, Keefer MC, et al; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120. J Acquir Immune Defic Syndr. 2007;44(2):203-212.
12. Goepfert PA, Horton H, McElrath MJ, et al; NIAID HIV Vaccine Trials Network. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 2005;192(7):1249-1259.
13. McCormack S, Stohr W, Barber T, et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008;26(25):3162-3174.
14. Priddy FH, Brown D, Kublin J, et al; Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46(11):1769-1781.
15. Cleghorn F, Pape JW, Schechter M, et al; 026 Protocol Team and the NIAID HIV Vaccine Trials Network. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007;46(2):222-230.
16. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455(7213):613-619.
17. Buchbinder SP, Mehrotra DV, Duerr A, et al; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study). Lancet. 2008;372(9653):1881-1893.
18. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654-665.
19. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
20. Schwartz DH, Mazumdar A, Winston S, Harkonen S. Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines. Clin Diagn Lab Immunol. 1995;2(3):268-271.
21. Silbermann B, Tod M, Desaint C, et al. Short communication: long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retroviruses. 2008;24(11):1445-1448.
22. Simonsen L, Buffington J, Shapiro CN, et al. Multiple false reactions in viral antibody screening assays after influenza vaccination. Am J Epidemiol. 1995;141(11):1089-1096.
23. Quirk EK, Mogg R, Brown DD, et al. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Clin Infect Dis. 2008;47(12):1593-1599.
24. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191(5):666-677. (Pubitemid 40271053)
25. McElrath MJ, De Rosa SC, Moodie Z, et al; Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894-1905.
26. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States. JAMA. 2008;300(8):945-951.
27. Centers for Disease Control and Prevention (CDC). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38(suppl 7):1-7.
28. Ackers ML, Parekh B, Evans TG, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis. 2003;187(6):879-886. (Pubitemid 36337899)
29. Khurana S, Needham J, Park S, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Acquir Immune Defic Syndr. 2006;43(3):304-312.
30. Gust DA, Wiegand RE, Para M, Chen RT, Bartholow BN. HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2009;52(2):294-298.